- Home
- NWPX vs NUWE Comparison
NWPX vs NUWE Comparison
Compare NWPX & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWPX
- NUWE
- Stock Information
- Founded
- NWPX 1966
- NUWE 1999
- Country
- NWPX United States
- NUWE United States
- Employees
- NWPX N/A
- NUWE N/A
- Industry
- NWPX Steel/Iron Ore
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NWPX Industrials
- NUWE Health Care
- Exchange
- NWPX Nasdaq
- NUWE Nasdaq
- Market Cap
- NWPX N/A
- NUWE 3.9M
- IPO Year
- NWPX 1995
- NUWE N/A
- Fundamental
- Price
- NWPX $38.56
- NUWE $0.96
- Analyst Decision
- NWPX Hold
- NUWE Strong Buy
- Analyst Count
- NWPX 1
- NUWE 1
- Target Price
- NWPX $55.00
- NUWE $17.00
- AVG Volume (30 Days)
- NWPX 56.0K
- NUWE 55.0K
- Earning Date
- NWPX 04-30-2025
- NUWE 05-13-2025
- Dividend Yield
- NWPX N/A
- NUWE N/A
- EPS Growth
- NWPX 37.25
- NUWE N/A
- EPS
- NWPX 3.27
- NUWE N/A
- Revenue
- NWPX $495,448,000.00
- NUWE $8,740,000.00
- Revenue This Year
- NWPX $2.48
- NUWE $22.96
- Revenue Next Year
- NWPX $4.49
- NUWE $29.97
- P/E Ratio
- NWPX $11.40
- NUWE N/A
- Revenue Growth
- NWPX 8.06
- NUWE N/A
- 52 Week Low
- NWPX $32.04
- NUWE $0.75
- 52 Week High
- NWPX $57.76
- NUWE $11.55
- Technical
- Relative Strength Index (RSI)
- NWPX 39.53
- NUWE 48.34
- Support Level
- NWPX $36.97
- NUWE $0.91
- Resistance Level
- NWPX $42.88
- NUWE $1.06
- Average True Range (ATR)
- NWPX 1.42
- NUWE 0.08
- MACD
- NWPX -0.34
- NUWE 0.01
- Stochastic Oscillator
- NWPX 25.08
- NUWE 44.50
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.